Walleye Capital LLC Takes $433,000 Position in Brainsway Ltd. Sponsored ADR $BWAY

Walleye Capital LLC acquired a new stake in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 32,576 shares of the company’s stock, valued at approximately $433,000.

A number of other large investors have also bought and sold shares of BWAY. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Brainsway during the 1st quarter worth approximately $40,000. Raymond James Financial Inc. acquired a new position in shares of Brainsway in the second quarter valued at approximately $85,000. Bank of America Corp DE bought a new stake in shares of Brainsway during the third quarter worth $107,000. Royal Bank of Canada increased its position in shares of Brainsway by 1,145.9% during the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after acquiring an additional 7,735 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Brainsway during the fourth quarter worth $209,000. 30.11% of the stock is owned by institutional investors.

Brainsway Price Performance

Shares of NASDAQ BWAY opened at $15.97 on Friday. The stock has a market capitalization of $640.86 million, a price-to-earnings ratio of 45.63 and a beta of 1.22. The business has a 50-day moving average of $15.02 and a 200-day moving average of $13.95. Brainsway Ltd. Sponsored ADR has a fifty-two week low of $5.68 and a fifty-two week high of $17.35.

Brainsway (NASDAQ:BWAY) last released its earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The business had revenue of $15.53 million for the quarter, compared to the consensus estimate of $14.63 million. On average, sell-side analysts expect that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday. New Street Research restated a “buy” rating on shares of Brainsway in a report on Friday. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research raised Brainsway from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Brainsway in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.67.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.